GLENMARKGlenmark Pharmaceuticals Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹60,224 Cr
Primary DriverBalance Sheet Stress
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
17 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in balance sheet stress. This indicates that forensic pressure is currently receding. Risk levels are improving.

48.5th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹2,184.6▼0.75%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress
+8.0 pts
Stability Adjustment
+9.0 pts
Final Composite Risk17 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 22 → 17 over 13 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Industrial Margin Stress
  • Operating Leverage Stress
What to Watch Next Quarter
  • Operating profit margins
  • Debt growth
  • Inventory turnover

Active Risk Objects (6)

CriticalHigh
Industrial Margin Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumDecaying
Last SignalQ4 FY2025
GLENMARK: EBITDA margin compressed by 13.9 bps YoY and Raw material costs consumed an additional 4.7% of revenue YoY.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Operating Leverage Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ2 FY2026
Expenses are consistently growing faster than revenues, creating operational pressure.

"The balance sheet is heavily over-leveraged. Interest payments are consuming most of the profit."

Profit Collapse
📊 Earnings QualityQuarterlyActive for 3 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ1 FY2026
GLENMARK: Net Profit collapsed by 86.2% from FY2025 Q1 to FY2026 Q1.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 3 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ4 FY2025
GLENMARK: Low Interest Coverage Ratio of 1.12x in FY2025 Q4 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ4 FY2025
Inventory growth (20.5%) significantly outpaced revenue growth (-14.8%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 22.6%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)8.757.70⚠️ HIGH
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+49.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹2,184.6(-0.75%)
1M Divergence-11.48%
1 Week-7.09%
1 Month-9.21%
6 Months+10.68%
1 Year+46.24%
2 Year+89%
3 Year+258.14%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

GLENMARK • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.94%
Trend QualityDeveloping
Phase Progression
Phase Progression Score65%
Readiness LabelModerate (Transition Potential Building)
Probability of Advancing94%
CoinTree Momentum
Composite Z-Score-0.2212σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#1462 of 2716
Top 53.83% in momentum strength
Timeframe Sparklines
1W-7.1%
1M-9.2%
6M+10.7%
Weinstein Indicators
150 DMA₹2,077.34
200 DMA₹2,053.9
150 DMA Slope+2.5855%Rising
Relative Strength+16.17%Leading
Relative Turnover (RTR)1.2863
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).
GLENMARKGlenmark Pharmaceuticals Limited
17 Risk
Sector %ile48th
Delta-5
Active Flags6
Accel+0
Balance Sheet Stress

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

AARTIPHARMAarti Pharmalabs Limited
35 Risk
Sector %ile81th
Delta0
Active Flags18
Accel+0
Earnings Quality

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
660th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Working Capital Expansion

2026

Operating Leverage Stress

2025

Industrial Margin Stress

2025

Inventory Stress

2025

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY202617,4431,3623,445-
FY202513,4351,047-8282,194
FY202412,653-1,434-265991
FY202313,3073776254,348